ASND Ascendis Pharma A/S IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1612042 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 247.50M | 213.63M | 158.04M | 100.95M | 173.92M | 57.83M | 36.00M | 95.89M |
| Cost of revenue | 23.60M | 22.35M | 31.45M | 17.52M | 14.02M | 11.20M | 11.46M | 7.57M |
| Gross profit | 223.90M | 191.28M | 126.60M | 83.44M | 159.89M | 46.63M | 24.53M | 88.33M |
| R&D expense | 78.15M | 66.88M | 71.99M | 86.60M | 79.30M | 73.54M | 83.48M | 70.69M |
| SG&A expense | 135.85M | 113.40M | 107.56M | 101.05M | 80.21M | 69.83M | 74.31M | 66.78M |
| Operating income | 9.90M | 11.00M | -52.95M | -104.21M | 383,000 | -96.74M | -133.26M | -49.15M |
| Interest expense | -64.06M | 66.90M | 33.02M | 44.79M | -4.98M | 25.35M | 19.62M | 77.16M |
| Pretax income | -26.70M | -57.37M | -35.01M | -93.56M | -37.38M | -98.18M | -109.15M | -128.53M |
| Income tax | 6.86M | 3.62M | 3.85M | 1.06M | 1.08M | 1.02M | 229,000 | 2.51M |
| Net income | -33.56M | -60.99M | -38.85M | -94.63M | -38.47M | -99.20M | -109.38M | -131.03M |
| EPS (basic) | — | -1.00 | -0.64 | -1.58 | — | -1.72 | -1.91 | -2.30 |
| EPS (diluted) | — | — | — | -1.58 | — | -1.72 | -1.91 | -2.30 |
| Weighted avg. shares (diluted) | — | — | 63.91M | — | — | — | 60.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | 616.04M | 539.09M | 494.05M | 517.92M | 559.54M | 625.51M | 258.70M | 320.24M |
| Receivables | 141.33M | 134.73M | 110.45M | 66.69M | 166.28M | 33.10M | 49.16M | 41.09M |
| Inventory | 301.53M | 302.02M | 303.38M | 293.07M | 295.61M | 265.43M | 251.20M | 232.68M |
| Current assets | 1.11B | 1.02B | 952.96M | 921.49M | 1.06B | 973.74M | 627.32M | 664.11M |
| PP&E, netmay include right-of-use assets (IFRS) | 146.48M | 101.76M | 93.54M | 92.45M | 98.71M | 97.52M | 104.04M | 107.16M |
| Total assets | 1.30B | 1.15B | 1.09B | 1.06B | 1.18B | 1.09B | 758.30M | 802.50M |
| Current liabilities | 1.07B | 986.48M | 935.00M | 885.51M | 907.86M | 838.46M | 847.74M | 798.97M |
| Short-term debt | 429.39M | 426.24M | 418.07M | 449.56M | 458.21M | 422.06M | 432.19M | 424.98M |
| Long-term debt | 385.25M | 331.37M | 330.19M | 357.31M | 365.08M | 338.93M | 219.05M | 229.63M |
| Total debt | 814.64M | 757.61M | 748.26M | 806.87M | 823.29M | 760.99M | 651.24M | 654.61M |
| Total liabilities | 1.47B | 1.33B | 1.28B | 1.25B | 1.29B | 1.19B | 1.08B | 1.04B |
| Shareholders' equity | -162.82M | -174.07M | -187.57M | -189.81M | -105.71M | -97.32M | -321.13M | -238.18M |
| Net debt | 198.60M | 218.52M | 254.21M | 288.95M | 263.74M | 135.48M | 392.55M | 334.37M |
| Cash flow statement | ||||||||
| Operating cash flow | 73.40M | 2.15M | -7.34M | -14.31M | -87.18M | -56.13M | -61.31M | -101.58M |
| Capital expenditure | — | — | — | — | — | 467,000 | 342,000 | 199,000 |
| Free cash flow | — | — | — | — | — | -56.60M | -61.65M | -101.78M |
| Investing cash flow | -3.39M | -53,000 | -4.34M | -703,000 | -384,000 | -503,000 | 608,000 | 7.16M |
| Financing cash flow | 8.52M | 38.85M | 6.98M | -18.02M | 87,000 | 427.87M | -2.46M | 18.42M |
| Stock-based compensation | 29.95M | 30.64M | 30.02M | 25.56M | 26.22M | 25.96M | 26.05M | 17.28M |
| Share buybacks | 0 | 0 | 0 | 17.40M | 0 | 0 | — | — |
Free plan shows the latest 8 periods; Pro shows all 36 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.